In Vitro and In Vivo High-throughput assays for the testing of Anti-trypanosoma cruzi compounds

PLoS Neglected Tropical Diseases

Volumn 4, Issue 7, 2010, Pages

  Canavaci, Adriana M C ^a   Bustamante, Juan M ^a   Padilla, Angel M ^a   Brandan, Cecilia M Perez ^b   Simpson, Laura J ^a   Xu, Dan ^a   Boehlke, Courtney L ^a   Tarleton, Rick L ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSIDAD NACIONAL DE SALTA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITRYPANOSOMAL AGENT; BENZNIDAZOLE; BIS 767; ENH 5; EXO 2 04; EXO 2 12; EXO 2 17; EXO 2 36; FIREFLY LUCIFERASE; FLUORESCENT DYE; NIFURTIMOX; NITROTRIAZOLE DERIVATIVE; POSACONAZOLE; TANDEM TOMATO FLUORESCENT PROTEIN; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT; PHOTOPROTEIN; VEGETABLE PROTEIN;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SCREENING; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; IC 50; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PARASITE VIRULENCE; PARASITEMIA; REPRODUCIBILITY; SIGNAL TRANSDUCTION; TRYPANOSOMA CRUZI; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECT; FOOT; GENETICS; METABOLISM; METHODOLOGY; MOUSE; PARASITOLOGY; REPORTER GENE; SENSITIVITY AND SPECIFICITY; STAINING;

ANIMALS; ANTIPROTOZOAL AGENTS; CHAGAS DISEASE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FOOT; GENES, REPORTER; HIGH-THROUGHPUT SCREENING ASSAYS; INHIBITORY CONCENTRATION 50; LUCIFERASES, FIREFLY; LUMINESCENT PROTEINS; MICE; MICE, INBRED BALB C; PLANT PROTEINS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STAINING AND LABELING; TRYPANOSOMA CRUZI;

EID: 77957157882     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000740     Document Type: Article

References (47)

1. WHO (2002) Control of Chagas disease. World Health Organ Tech Rep Ser 905: i-vi, 1-109, back cover.
2. Schofield CJ, Jannin J, Salvatella R (2006) The future of Chagas disease control. Trends Parasitol 22: 583-588.
3. Rodriques Coura J, de Castro SL (2002) A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 97: 3-24.
4. Bern C, Montgomery SP, Herwaldt BL, Rassi A, Jr., Marin-Neto JA, et al. (2007) Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA 298: 2171-2181.
5. Viotti R, Vigliano C, Lococo B, Alvarez MG, Petti M, et al. (2009) Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther 7: 157-163.
6. Urbina JA. Specific chemotherapy of Chagas disease: Relevance, current limitations and new approaches. Acta Tropica, In Press, Corrected Proof.
7. Rolon M, Vega C, Escario JA, Gomez-Barrio A (2006) Development of resazurin microtiter assay for drug sensibility testing of Trypanosoma cruzi epimastigotes. Parasitol Res 99: 103-107.
8. Muelas-Serrano S, Nogal-Ruiz JJ, Gomez-Barrio A (2000) Setting of a colorimetric method to determine the viability of Trypanosoma cruzi epimastigotes. Parasitol Res 86: 999-1002.
9. Kouznetsov VV, Castro JR, Puentes CO, Stashenko EE, Martinez JR, et al. (2005) Synthesis and antiparasitic properties of new 4-N-benzylamino-4- hetarylbut-1-enes. Arch Pharm (Weinheim) 338: 32-37.
10. Vega C, Rolon M, Martinez-Fernandez AR, Escario JA, Gomez-Barrio A (2005) A new pharmacological screening assay with Trypanosoma cruzi epimastigotes expressing beta-galactosidase. Parasitol Res 95: 296-298.
11. Saraiva J, Vega C, Rolon M, da Silva R, Andrade e Silva ML, et al. (2007) In vitro and in vivo activity of lignan lactones derivatives against Trypanosoma cruzi. Parasitol Res 100: 791-795.
12. Raz B, Iten M, Grether-Buhler Y, Kaminsky R, Brun R (1997) The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. Acta Trop 68: 139-147.
13. Neres J, Brewer ML, Ratier L, Botti H, Buschiazzo A, et al. (2009) Discovery of novel inhibitors of Trypanosoma cruzi trans-sialidase from in silico screening. Bioorg Med Chem Lett 19: 589-596.
14. Martinez-Diaz RA, Escario JA, Nogal-Ruiz JJ, Gomez-Barrio A (2001) Biological characterization of Trypanosoma cruzi strains. Mem Inst Oswaldo Cruz 96: 53-59.
15. Buckner FS, Verlinde CL, La Flamme AC, Van Voorhis WC (1996) Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase. Antimicrob Agents Chemother 40: 2592-2597.
16. Pires SF, DaRocha WD, Freitas JM, Oliveira LA, Kitten GT, et al. (2008) Cell culture and animal infection with distinct Trypanosoma cruzi strains expressing red and green fluorescent proteins. Int J Parasitol 38: 289-297.
17. Bettiol E, Samanovic M, Murkin AS, Raper J, Buckner F, et al. (2009) Identification of three classes of heteroaromatic compounds with activity against intracellular Trypanosoma cruzi by chemical library screening. PLoS Negl Trop Dis 3: e384.
18. Engel JC, Doyle PS, Hsieh I, McKerrow JH (1998) Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J Exp Med 188: 725-734.
19. Urbina JA, Docampo R (2003) Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol 19: 495-501.
20. Romanha AJ, Alves RO, Murta SM, Silva JS, Ropert C, et al. (2002) Experimental chemotherapy against Trypanosoma cruzi infection: essential role of endogenous interferon-gamma in mediating parasitologic cure. J Infect Dis 186: 823-828.
21. Araujo MS, Martins-Filho OA, Pereira ME, Brener Z (2000) A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease. J Antimicrob Chemother 45: 819-824.
22. Molina J, Martins-Filho O, Brener Z, Romanha AJ, Loebenberg D, et al. (2000) Activities of the Triazole Derivative SCH 56592 (Posaconazole) against Drug- Resistant Strains of the Protozoan Parasite Trypanosoma (Schizotrypanum) cruzi in Immunocompetent and Immunosuppressed Murine Hosts. Antimicrob Agents Chemother 44: 150-155.
23. Tyler KM, Engman DM (2000) Flagellar elongation induced by glucose limitation is preadaptive for Trypanosoma cruzi differentiation. Cell Motil Cytoskeleton 46: 269-278.
24. Bourguignon SC, de Souza W, Souto-Padron T (1998) Localization of lectinbinding sites on the surface of Trypanosoma cruzi grown in chemically defined conditions. Histochem Cell Biol 110: 527-534.
25. Shaner NC, Campbell RE, Steinbach PA, Giepmans BN, Palmer AE, et al. (2004) Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol 22: 1567-1572.
26. Vazquez MP, Levin MJ (1999) Functional analysis of the intergenic regions of TcP2beta gene loci allowed the construction of an improved Trypanosoma cruzi expression vector. Gene 239: 217-225.
27. Chtanova T, Schaeffer M, Han SJ, van Dooren GG, Nollmann M, et al. (2008) Dynamics of neutrophil migration in lymph nodes during infection. Immunity 29: 487-496.
28. Xu D, Brandan CP, Basombrio MA, Tarleton RL (2009) Evaluation of high efficiency gene knockout strategies for Trypanosoma cruzi. BMC Microbiol 9: 90.
29. Yarrow JC, Feng Y, Perlman ZE, Kirchhausen T, Mitchison TJ (2003) Phenotypic screening of small molecule libraries by high throughput cell imaging. Comb Chem High Throughput Screen 6: 279-286.
30. Feng Y, Yu S, Lasell TK, Jadhav AP, Macia E, et al. (2003) Exo1: a new chemical inhibitor of the exocytic pathway. Proc Natl Acad Sci U S A 100: 6469-6474.
31. Feng Y, Jadhav AP, Rodighiero C, Fujinaga Y, Kirchhausen T, et al. (2004) Retrograde transport of cholera toxin from the plasma membrane to the endoplasmic reticulum requires the trans-Golgi network but not the Golgi apparatus in Exo2-treated cells. EMBO Rep 5: 596-601.
32. Aponte JC, Vaisberg AJ, Castillo D, Gonzalez G, Estevez Y, et al. (2010) Trypanoside, Anti-Tuberculosis, Leishmanicidal and Cytotoxic Activity of Tetrahydrobenzothienopyrimidines. Bioorganic & Medicinal Chemistry;in press.
33. Yan W, Moreno SN (1998) A method to assess invasion and intracellular replication of Trypanosoma cruzi based on differential uracil incorporation. J Immunol Methods 220: 123-128.
34. Nagappan V, Deresinski S (2007) Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 45: 1610-1617.
35. Fradkov AF, Verkhusha VV, Staroverov DB, Bulina ME, Yanushevich YG, et al. (2002) Far-red fluorescent tag for protein labelling. Biochem J 368: 17-21.
36. Winnard PT, Jr., Kluth JB, Raman V (2006) Noninvasive optical tracking of red fluorescent protein-expressing cancer cells in a model of metastatic breast cancer. Neoplasia 8: 796-806.
37. Guevara P, Dias M, Rojas A, Crisante G, Abreu-Blanco MT, et al. (2005) Expression of fluorescent genes in Trypanosoma cruzi and Trypanosoma rangeli (Kinetoplastida: Trypanosomatidae): its application to parasite-vector biology. J Med Entomol 42: 48-56.
38. Lorenzi HA, Vazquez MP, Levin MJ (2003) Integration of expression vectors into the ribosomal locus of Trypanosoma cruzi. Gene 310: 91-99.
39. Ochoa C, Perez E, Perez R, Suarez M, Ochoa E, et al. (1999) Synthesis and antiprotozoan properties of new 3,5-disubstituted-tetrahydro-2H-1,3,5-thiadiazine- 2-thione derivatives. Arzneimittelforschung 49: 764-769.
40. Lopes AA, Lopez SN, Regasini LO, Junior JM, Ambrosio DL, et al. (2008) In vitro activity of compounds isolated from Piper crassinervium against Trypanosoma cruzi. Nat Prod Res 22: 1040-1046.
41. Batista JM, Jr., Lopes AA, Ambrosio DL, Regasini LO, Kato MJ, et al. (2008) Natural chromenes and chromene derivatives as potential anti-trypanosomal agents. Biol Pharm Bull 31: 538-540.
42. Ferraz ML, Gazzinelli RT, Alves RO, Urbina JA, Romanha AJ (2007) The Anti-Trypanosoma cruzi Activity of Posaconazole in a Murine Model of Acute Chagas' Disease Is Less Dependent on Gamma Interferon than That of Benznidazole. Antimicrob Agents Chemother 51: 1359-1364.
43. Bustamante JM, Bixby LM, Tarleton RL (2008) Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat Med 14: 542-550.
44. Tarleton RL, Reithinger R, Urbina JA, Kitron U, Gurtler RE (2007) The challenges of Chagas Disease- grim outlook or glimmer of hope. PLoS Med 4: e332.
45. Reithinger R, Tarleton RL, Urbina JA, Kitron U, Gurtler RE (2009) Eliminating Chagas disease: challenges and a roadmap. BMJ 338: b1283.
46. Hyland KV, Asfaw SH, Olson CL, Daniels MD, Engman DM (2008) Bioluminescent imaging of Trypanosoma cruzi infection. Int J Parasitol 38: 1391-1400.
47. DaRocha WD, Silva RA, Bartholomeu DC, Pires SF, Freitas JM, et al. (2004) Expression of exogenous genes in Trypanosoma cruzi: improving vectors and electroporation protocols. Parasitol Res 92: 113-120.